Literature DB >> 2897972

Mitogenic activity on parathyroid cells in plasma from members of a large kindred with multiple endocrine neoplasia type 1.

S J Marx1, K Sakaguchi, J Green, G D Aurbach, M L Brandi.   

Abstract

We tested plasma from 83 members of a large kindred with familial multiple endocrine neoplasia type 1 (FMEN1) for mitogenic activity on cultured bovine parathyroid cells. We evaluated the age dependency of parathyroid mitogenic activity (PMA) in plasma from affected and unaffected members of the kindred, and we analyzed the relation of plasma PMA to indices of activity of parathyroid, pancreatic islet, and anterior pituitary tissue. Plasma PMA was higher in members expressing the FMEN1 gene than in their unaffected first, second, third, or fourth degree relatives (P less than 0.05), and 10 of 20 members expressing the FMEN1 gene had plasma PMA above the 95% limit of the control range. Plasma PMA was not dependent on sex or age; the lack of age dependency and the high values in FMEN1 gene carriers suggested that plasma PMA is elevated in some FMEN1 gene carriers very early in life. Plasma PMA in known gene carriers varied significantly with one index of parathyroid function [plasma PMA was 2.5 times higher in the group with than in the group without prior parathyroidectomy (P less than 0.005), an indicator of more severe prior parathyroid disease] and correlated positively, although not significantly so, with indices of pancreatic islet function (serum gastrin by RIA) and anterior pituitary function (serum PRL by RIA). In summary, (1) plasma PMA levels are high in many known carriers of the FMEN1 gene, (2) the high plasma PMA levels in FMEN1 may precede overt endocrine hyperfunction; and (3) high plasma PMA levels vary with one index of parathyroid function, but do not correlate with indices of pancreatic islet or anterior pituitary function in members expressing the FMEN1 gene. The high plasma PMA levels in FMEN1 may be the direct cause of hyperfunction of the parathyroids, but the relation of high plasma PMA to hyperfunction of the pancreatic islets and anterior pituitary is uncertain.

Entities:  

Mesh:

Year:  1988        PMID: 2897972     DOI: 10.1210/jcem-67-1-149

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Coexistent multiple myeloma and MEN type 1.

Authors:  E Romagnoli; S Minisola; V Carnevale; G Spagna; E D'Erasmo; G Mazzuoli
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

2.  Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D'etude des Néoplasies Endocriniennes Multiples Study Group.

Authors:  P Goudet; P Cougard; B Vergès; A Murat; B Carnaille; A Calender; J Faivre; C Proye
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

3.  Proliferation of endothelial component of parathyroid gland in multiple endocrine neoplasia type 1. Potential relationship with a mitogenic factor.

Authors:  T D'Adda; A Amorosi; G Bussolati; M L Brandi; C Bordi
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

4.  Expression of basic fibroblast growth factor in hyperplastic parathyroid glands from patients with multiple endocrine neoplasia type I.

Authors:  M Komatsu; S Tsuchiya; I Matsuyama; S Kaneko; Y Suzuki; N Ito; N Hanamura; T Seki; S Kobayashi; T Kuroda
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

5.  Insulin-like growth factor I receptors and insulin-like growth factor-binding proteins in human parathyroid tumors.

Authors:  R Tanaka; T Tsushima; H Murakami; K Shizume; T Obara
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

6.  Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Marc J Berna; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2013-05       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.